Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Journal of Personalized Medicine|August 27, 2021
Targeted Therapy in Acute Lymphoblastic LeukaemiaRoss Salvaris, Pasquale Luke FedeleFuture Oncology (London, England)|October 16, 2020
An update of venetoclax and obinutuzumab in chronic lymphocytic leukemiaRoss Salvaris, Stephen OpatJournal of Personalized Medicine|May 5, 2021
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell LymphomasRoss Salvaris, Jeremy Ong, Gareth P GregoryInternal Medicine Journal|November 11, 2023
Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemiaRoss Salvaris, Stephen Mulligan, Andrea Puig, et al.Leukemia & Lymphoma|May 26, 2026
Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry studyZoe Loh, Eliza Chung, Cameron Wellard, et al.British Journal of Haematology|April 14, 2021
Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 yearsZoe Loh, Ross Salvaris, Geoffrey Chong, et al.Blood Cell Therapy|January 30, 2023
Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant PatientsRoss Salvaris, Sam Salman, Sean O'Halloran, et al.The Journal of Infectious Diseases|April 12, 2012
Illness severity in community-onset invasive Staphylococcus aureus infection and the presence of virulence genesMichael C Wehrhahn, J Owen Robinson, Elaine M Pascoe, et al.Internal Medicine Journal|June 17, 2024
Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma AllianceMasa Lasica, Mary A Anderson, Alex Boussioutas, et al.Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.Pageof 2